Updated Jun 24, 10:50 PM · 60 sources analyzed
Key Takeaways
AstraZeneca terminated all three brazikumab IBD trials simultaneously, signaling a full strategic exit from the IL-23 IBD class without disclosing efficacy data.
A preprint identifies TI-374 as a sub-micromolar TB killer via alanine auxotrophy — a first-in-class mechanism that could expand the anti-TB toolkit.
Multiple Phase 2 and Phase 3 completions today (Clexio MDD, Lumos Pharma GHD, OSE-127 UC) leave pending data readouts as the next catalysts to watch.
🏆 Winner
OSE Immunotherapeutics — Phase 2 UC trial completion positions it as a differentiated IBD asset with a novel CD127 mechanism at the exact moment AstraZeneca vacates the space.
📉 Loser
AstraZeneca — simultaneous termination of all brazikumab IBD programs represents a full write-off of its IL-23 inhibitor investment across two indications with no data explanation offered.
🔭 Watch Next
The most consequential near-term event visible in today's sources is the pending topline data release from Clexio Biosciences' Phase 2 oral esketamine (CLE-100) study in treatment-resistant MDD, which could validate a differentiated oral route in a large market dominated by Janssen's intranasal Spravato.
AstraZeneca terminates brazikumab across all IBD programs
AstraZeneca has terminated three separate brazikumab trials — a Phase 2 and open-label extension in ulcerative colitis and a Phase 2/3 study in Crohn's disease — marking a full exit from the IL-23 inhibitor's inflammatory bowel disease program. The simultaneous termination across UC and Crohn's disease indications signals a strategic decision rather than a single trial failure, though no efficacy or safety data explaining the discontinuations have been released by AstraZeneca. The IBD space remains intensely competitive with approved IL-23 inhibitors already on market, and this exit removes AstraZeneca as a potential challenger in that class.
ClinicalTrials.gov ↗AstraZeneca
Brazikumab in Crohn's Disease / Ulcerative Colitis (IBD)
Three brazikumab trials have been marked Terminated on ClinicalTrials.gov: a Phase 2/3 study in Crohn's disease (NCT03759288), a Phase 2 induction study in UC (NCT03616821), and a Phase 2 open-label extension in UC (NCT04277546). No efficacy or safety data explaining the terminations have been released; the company has not issued a press release.
Why it matters
The simultaneous shutdown across both UC and Crohn's indications, without any disclosed data, suggests a portfolio prioritization call rather than a single clinical failure — but the absence of a public explanation leaves open questions about whether efficacy, safety, or competitive economics drove the decision. Until AstraZeneca clarifies the rationale, investors in competing IBD programs can interpret this as one less late-stage entrant in the IL-23 class.
What to watch
Watch for AstraZeneca to address the brazikumab termination rationale at its next investor event or pipeline update, and whether it pivots IBD R&D spending toward other mechanisms in its portfolio.
TI-374 induces alanine auxotrophy to kill Mycobacterium tuberculosis at sub-micromolar concentrations
A drug-repurposing screen identified TI-374, a hydroxamic acid compound, that kills Mycobacterium tuberculosis by inducing alanine auxotrophy (making the bacterium unable to synthesize the amino acid alanine it needs to survive) through a previously unexploited mechanism, with activity at sub-micromolar concentrations.
Why it matters
With global TB drug pipelines heavily reliant on a handful of mechanisms — bedaquiline, nitroimidazoles, oxazolidinones — a validated new target in alanine biosynthesis is a genuinely distinct opportunity for TB-focused developers and global health funders. The repurposing origin of TI-374 also lowers the early de-risking bar compared to a de novo discovery program.
What to watch
Watch for preclinical in vivo efficacy and pharmacokinetic data from TI-374 or optimized analogs to determine whether the alanine auxotrophy mechanism translates to animal TB infection models, which would be the gateway to IND-enabling studies.
Clexio Biosciences
CLE-100 (oral esketamine) in Major Depressive Disorder (MDD)
The Phase 2 double-blind, randomized, placebo-controlled study of CLE-100 as adjunctive treatment in MDD patients with inadequate response to standard antidepressants has been marked Completed on ClinicalTrials.gov. Full efficacy and safety data have not yet been released; the company has not issued a press release disclosing topline results.
Why it matters
The completion of a placebo-controlled Phase 2 in treatment-resistant MDD is a meaningful pipeline checkpoint for Clexio, but the investment thesis hinges entirely on the efficacy data that have yet to be disclosed. The oral route of administration is a genuine differentiator from Spravato if tolerability and abuse-risk data support it.
What to watch
Watch for Clexio to release topline Phase 2 data at a psychiatry conference or via press release, likely in the second half of 2026, which will determine whether the oral esketamine program advances to Phase 3.
Alexion Pharmaceuticals (AstraZeneca)
CAEL-101 in AL Amyloidosis (Mayo Stage IIIa)
The Phase 3 CARES trial of CAEL-101 in Mayo Stage IIIa AL amyloidosis (NCT04512235) is listed as Active, Not Recruiting on ClinicalTrials.gov. No efficacy or outcome data have been disclosed; this is a registry status update only.
Why it matters
The trial's active-not-recruiting status means CAEL-101's Phase 3 readout is on the horizon, which will be a high-stakes moment for Alexion's rare disease pipeline — the data will need to show not just statistical significance but a meaningful survival benefit in a patient population with poor prognosis.
What to watch
Watch for the CARES Phase 3 primary endpoint readout, expected to include overall survival data, and whether Alexion files for accelerated approval or pursues a full BLA based on the results.
Three brazikumab trials have been marked Terminated on ClinicalTrials.gov: a Phase 2/3 study in Crohn's disease (NCT03759288), a Phase 2 induction study in UC (NCT03616821), and a Phase 2 open-label extension in UC (NCT04277546). No efficacy or safety data explaining the terminations have been released; the company has not issued a press release.
Why it matters
A full-program termination removes AstraZeneca from the crowded IL-23 inhibitor IBD market, where Janssen's guselkumab, AbbVie's risankizumab, and Eli Lilly's mirikizumab already hold or are pursuing approvals.
Analysis
The simultaneous shutdown across both UC and Crohn's indications, without any disclosed data, suggests a portfolio prioritization call rather than a single clinical failure — but the absence of a public explanation leaves open questions about whether efficacy, safety, or competitive economics drove the decision. Until AstraZeneca clarifies the rationale, investors in competing IBD programs can interpret this as one less late-stage entrant in the IL-23 class.
What to watch
Watch for AstraZeneca to address the brazikumab termination rationale at its next investor event or pipeline update, and whether it pivots IBD R&D spending toward other mechanisms in its portfolio.
The Phase 2 double-blind, randomized, placebo-controlled study of CLE-100 as adjunctive treatment in MDD patients with inadequate response to standard antidepressants has been marked Completed on ClinicalTrials.gov. Full efficacy and safety data have not yet been released; the company has not issued a press release disclosing topline results.
Why it matters
Oral esketamine formulations represent a potentially more convenient alternative to Janssen's intranasal Spravato; completion of this Phase 2 sets up a potential data readout that could clarify CLE-100's competitive viability.
Analysis
The completion of a placebo-controlled Phase 2 in treatment-resistant MDD is a meaningful pipeline checkpoint for Clexio, but the investment thesis hinges entirely on the efficacy data that have yet to be disclosed. The oral route of administration is a genuine differentiator from Spravato if tolerability and abuse-risk data support it.
What to watch
Watch for Clexio to release topline Phase 2 data at a psychiatry conference or via press release, likely in the second half of 2026, which will determine whether the oral esketamine program advances to Phase 3.
The Phase 3 CARES trial of CAEL-101 in Mayo Stage IIIa AL amyloidosis (NCT04512235) is listed as Active, Not Recruiting on ClinicalTrials.gov. No efficacy or outcome data have been disclosed; this is a registry status update only.
Why it matters
AL amyloidosis remains an area of high unmet need with limited approved therapies targeting amyloid fibril clearance; the enrollment completion of CARES keeps CAEL-101 on track as a potentially important add-on to plasma cell-directed treatment.
Analysis
The trial's active-not-recruiting status means CAEL-101's Phase 3 readout is on the horizon, which will be a high-stakes moment for Alexion's rare disease pipeline — the data will need to show not just statistical significance but a meaningful survival benefit in a patient population with poor prognosis.
What to watch
Watch for the CARES Phase 3 primary endpoint readout, expected to include overall survival data, and whether Alexion files for accelerated approval or pursues a full BLA based on the results.
The Phase 2 OraGrowtH210 Trial of LUM-201 in children with growth hormone deficiency has been marked Completed on ClinicalTrials.gov. The study investigated LUM-201 and a predictive enrichment marker (PEM) strategy to identify responsive patients. Full efficacy and safety data have not been released in conjunction with this registry update.
Why it matters
An oral growth hormone secretagogue with a validated patient-selection biomarker could meaningfully disrupt a market dominated by daily injectable recombinant growth hormone if the efficacy data support the PEM-selected approach.
Analysis
Lumos Pharma's PEM strategy — using a biomarker to enrich for likely responders — is the scientific bet that differentiates LUM-201 from a crowded injectable field; the Phase 2 completion means investors will now be focused on whether the enrichment strategy produced clean enough data to support a pivotal program.
What to watch
Watch for Lumos Pharma to present or publish OraGrowtH210 results, which will determine whether a Phase 3 enrichment-design trial is warranted and whether the FDA aligns with the PEM selection criterion.
The Phase 2 multicenter, randomized, double-blind, placebo-controlled study of OSE-127 in moderate-to-severe active ulcerative colitis has been marked Completed on ClinicalTrials.gov. No topline efficacy or safety results have been disclosed alongside this registry update.
Why it matters
OSE-127 targets CD127 (the IL-7 receptor alpha chain), a mechanism distinct from approved IL-12/23 and integrin inhibitors; a positive Phase 2 readout would validate a novel immunological pathway in IBD at a time when AstraZeneca is exiting the space.
Analysis
With AstraZeneca terminating its IBD program today, attention in the UC pipeline will shift to differentiated mechanisms, making OSE-127's pending data readout more visible to BD teams scanning for next-generation assets. The absence of data disclosure at this registry update is the key overhang.
What to watch
Watch for OSE Immunotherapeutics to release Phase 2 topline results, which could come at a gastroenterology congress or via press release in the coming months, and whether efficacy is sufficient to attract a partnership.
TI-374 induces alanine auxotrophy to kill Mycobacterium tuberculosis at sub-micromolar concentrations
A drug-repurposing screen identified TI-374, a hydroxamic acid compound, that kills Mycobacterium tuberculosis by inducing alanine auxotrophy (making the bacterium unable to synthesize the amino acid alanine it needs to survive) through a previously unexploited mechanism, with activity at sub-micromolar concentrations.
Why it matters
A first-in-class mechanism targeting alanine biosynthesis could provide a new scaffold for TB drug combinations at a time when resistance to existing regimens is a growing concern, and the sub-micromolar potency suggests a favorable starting point for medicinal chemistry optimization.
Analysis
With global TB drug pipelines heavily reliant on a handful of mechanisms — bedaquiline, nitroimidazoles, oxazolidinones — a validated new target in alanine biosynthesis is a genuinely distinct opportunity for TB-focused developers and global health funders. The repurposing origin of TI-374 also lowers the early de-risking bar compared to a de novo discovery program.
What to watch
Watch for preclinical in vivo efficacy and pharmacokinetic data from TI-374 or optimized analogs to determine whether the alanine auxotrophy mechanism translates to animal TB infection models, which would be the gateway to IND-enabling studies.
GSK's altSonflex1-2-3 Shigella vaccine demonstrates first-in-human safety and immunogenicity across age groups
GSK's Phase 1/2 first-in-human study of altSonflex1-2-3, a candidate vaccine targeting Shigella sonnei and Shigella flexneri serotypes 1b, 2a, and 3a, has completed, covering adults, children, and infants, with safety and immunogenicity as the primary objectives.
Why it matters
Shigellosis (bacterial dysentery caused by Shigella) lacks an approved vaccine globally, and a multivalent candidate with demonstrated first-in-human tolerability across age groups — including infants, the highest-burden population — would be a meaningful step toward addressing a significant global health gap.
Analysis
GSK completing a pediatric-inclusive first-in-human Shigella vaccine study is a low-profile but strategically important data point given the increasing BARDA and GAVI interest in enteric disease prevention; the immunogenicity results will determine whether the antigen design warrants investment in a larger efficacy trial.
What to watch
Watch for GSK to present immunogenicity data from the altSonflex1-2-3 study at an infectious disease or vaccinology conference, and whether the data support advancing to a Phase 2b field efficacy study in endemic regions.
Tislelizumab plus IL-2 and CapeOX neoadjuvant regimen studied in locally advanced rectal cancer
A prospective multicenter randomized Phase 2 study evaluating tislelizumab (an anti-PD-1 antibody) combined with interleukin-2 and CapeOX chemotherapy as neoadjuvant therapy (treatment before surgery) in locally advanced rectal cancer has been marked Completed, with ORR (the share of patients whose tumors shrank) and pathological complete response rate as key endpoints.
Why it matters
Adding IL-2 to PD-1 plus chemotherapy in the neoadjuvant rectal cancer setting explores whether broader immune activation — beyond checkpoint inhibition alone — can improve surgical outcomes, which is relevant to the growing interest in organ-preservation strategies in colorectal cancer.
Analysis
The rectal cancer neoadjuvant space is increasingly competitive, with total neoadjuvant therapy regimens and checkpoint inhibitors in MSI-H tumors already reshaping practice; the IL-2 addition is a scientific bet on enhanced T-cell expansion, and the trial results will clarify whether that combination adds measurable benefit beyond standard pembrolizumab-based approaches.
What to watch
Watch for the study's pathological complete response and ORR data to be presented at a GI oncology meeting, which will indicate whether the IL-2 addition justifies the added toxicity burden in a neoadjuvant context.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
No coverage today
None of your tracked companies appeared in today's sources.